Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of HPN-100 vs Buphenyl in Urea Cycle Disorders
NCT00551200Phase 2Completed
- Sponsor
- Amgen
- Start
- Oct 2007
- Primary completion
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sodium phenylbutyrate in urea cycle disorders (UCD), sponsored by Amgen. Started Oct 2007; status: completed.
02
Drugs
sodium phenylbutyrate
03
Conditions
urea cycle disorders (UCD)
Beyond the preview
Go deeper on NCT00551200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00551200.